13F reference period
Q2 2026
Security Snapshot
Coherus Oncology, Inc. - Common Stock (CHRS) Institutional Ownership
CUSIP: 19249H103
13F Institutional Holders and Ownership History from Q4 2014 to Q3 2026
Institutions Reporting
145
Shares (Excl. Options)
70.31M
Full value: 70,314,747 · shares · 30 Jun 2026Price
$1.40
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CHRS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 70,314,747
- Total 13F value
- $98,456,414
- Portfolio coverage rank
- 0%
- Share change
- -1,156,479
- Value change
- -$2,900,535
- Number of holders
- 145
- Shares outstanding
- 154,050,897
- SEC-reported price per share
- $1.21
- Insider filing price
- $1.21
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CHRS - Coherus Oncology, Inc. - Common Stock is tracked under CUSIP 19249H103.
- 145 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 158 to 145 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$120.79M
Full value: $120,792,356 · USD · 31 Mar 2026.$98.46M
Full value: $98,456,414 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 145 institutions filings for Q2 2026.
Security key
19249H103
13F reference period
Q2 2026
13F holders
145
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
CHRS full holder history
Coherus Oncology, Inc. SEC filings
Coherus Oncology, Inc. company facts
Coherus Oncology, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 19249H103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CHRS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 8.3% | +0.38% | $21,803,868 | -$68,400 | 12,750,800 | -0.31% | Timothy G. Youngquist 2020 Irrevocable Trust | 31 Mar 2026 |
| BlackRock, Inc. | 5.8% | +18% | $12,508,933 | +$2,236,767 | 8,934,952 | +22% | BlackRock, Inc. | 30 Jun 2026 |
| Bering Partners II, L.P. | 6.5% | $12,468,441 | 7,602,708 | Evgeny Zaytsev ("Zaytsev") | 05 Sep 2025 | |||
| SATTERFIELD THOMAS A JR | 4.6% | -12% | $11,711,700 | +$1,555,621 | 6,930,000 | +15% | Thomas A. Satterfield, Jr. | 31 Mar 2026 |
| Rubric Capital Management LP | 4.6% | $5,258,754 | 5,258,754 | Rubric Capital Management LP | 31 Dec 2024 |
As of 30 Jun 2026,
145
institutional investors reported holding
shares of
Coherus Oncology, Inc. - Common Stock (CHRS).
This represents
46%
of the company’s total
outstanding shares.
70.31M
Full value: 70,314,747 · shares · 30 Jun 2026154.05M
Full value: 154,050,897 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
42%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 8.5% | 13,050,623 | +6.2% | 3.7% | $18,270,872 |
| BlackRock, Inc. | 7.8% | 12,003,316 | +16% | 0% | $16,804,642 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 5,949,490 | +9.1% | 0% | $8,329,286 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 3,685,567 | +18% | 0% | $5,161,010 |
| SAMSARA BIOCAPITAL, LLC | 2.2% | 3,428,571 | 0% | 0.39% | $4,799,999 |
| Kohlberg Kravis Roberts & Co. L.P. | 2% | 3,036,076 | 0% | 0.07% | $4,184,019 |
| STATE STREET CORP | 1.5% | 2,382,305 | +2.4% | 0% | $3,335,227 |
| TWO SIGMA INVESTMENTS, LP | 1.5% | 2,259,412 | -1.9% | 0% | $3,163,177 |
| CM Management, LLC | 1.4% | 2,100,000 | 0% | 1.9% | $2,940,000 |
| C WorldWide Group Holding A/S | 1.3% | 1,928,464 | 0% | 0.07% | $2,700,000 |
| Alyeska Investment Group, L.P. | 1.1% | 1,733,234 | -23% | 0.01% | $2,426,528 |
| Hudson Bay Capital Management LP | 1.1% | 1,693,000 | -0.7% | 0.01% | $2,370,200 |
| AQR CAPITAL MANAGEMENT LLC | 0.86% | 1,330,201 | +10% | 0% | $1,862,281 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.8% | 1,228,069 | +6.2% | 0% | $1,719,297 |
| PANAGORA ASSET MANAGEMENT INC | 0.74% | 1,137,325 | -22% | 0% | $1,592,255 |
| NORTHERN TRUST CORP | 0.73% | 1,129,470 | +24% | 0% | $1,581,259 |
| VANGUARD FIDUCIARY TRUST CO | 0.66% | 1,015,991 | +7% | 0% | $1,422,387 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.58% | 899,999 | 0% | 0% | $1,260,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.57% | 883,454 | +46% | 0% | $1,236,836 |
| UBS Group AG | 0.49% | 760,358 | +39% | 0% | $1,064,501 |
| GOLDMAN SACHS GROUP INC | 0.39% | 602,075 | -14% | 0% | $842,905 |
| RENAISSANCE TECHNOLOGIES LLC | 0.37% | 563,056 | +70% | 0% | $788,278 |
| STRS OHIO | 0.26% | 395,600 | +22% | 0% | $553,840 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.25% | 391,000 | -11% | 0.01% | $547,400 |
| GSA CAPITAL PARTNERS LLP | 0.25% | 379,355 | +19% | 0.03% | $531,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
48
Headline period
Q2 2026
Rows shown
1-25 of 48
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 13,372,359 | $16,176,807 | -$97,460 | $1.21 | 22 |
| 2026 Q2 | 70,314,747 | $98,456,414 | -$2,900,535 | $1.40 | 145 |
| 2026 Q1 | 71,564,602 | $120,792,356 | +$29,462,872 | $1.69 | 158 |
| 2025 Q4 | 51,226,608 | $72,711,760 | -$2,068,458 | $1.42 | 126 |
| 2025 Q3 | 51,511,878 | $84,436,218 | -$2,969,339 | $1.64 | 110 |
| 2025 Q2 | 55,358,578 | $40,439,575 | -$4,928,963 | $0.73 | 109 |
| 2025 Q1 | 62,082,313 | $50,064,190 | -$6,457,989 | $0.81 | 114 |
| 2024 Q4 | 65,594,814 | $90,489,403 | -$12,493,801 | $1.38 | 121 |
| 2024 Q3 | 76,943,748 | $79,924,458 | -$11,982,900 | $1.04 | 127 |
| 2024 Q2 | 82,580,425 | $142,867,620 | -$603,275 | $1.73 | 132 |
| 2024 Q1 | 82,494,208 | $197,162,680 | -$5,908,937 | $2.39 | 134 |
| 2023 Q4 | 81,477,441 | $271,309,409 | -$37,399,801 | $3.33 | 153 |
| 2023 Q3 | 92,968,604 | $347,619,918 | +$14,526,156 | $3.74 | 168 |
| 2023 Q2 | 86,685,207 | $370,290,994 | +$30,644,927 | $4.27 | 159 |
| 2023 Q1 | 78,433,333 | $536,456,842 | -$2,030,485 | $6.84 | 163 |
| 2022 Q4 | 78,672,183 | $622,985,097 | +$2,380,758 | $7.92 | 160 |
| 2022 Q3 | 77,664,501 | $746,258,214 | -$14,908,210 | $9.61 | 168 |
| 2022 Q2 | 78,904,235 | $571,951,639 | +$12,362,063 | $7.24 | 171 |
| 2022 Q1 | 75,936,074 | $979,679,788 | -$19,093,537 | $12.91 | 172 |
| 2021 Q4 | 76,732,060 | $1,226,275,602 | +$9,148,757 | $15.96 | 190 |
| 2021 Q3 | 76,118,247 | $1,224,124,361 | -$23,896,897 | $16.07 | 182 |
| 2021 Q2 | 77,861,825 | $1,077,307,964 | -$38,365,571 | $13.83 | 184 |
| 2021 Q1 | 80,296,427 | $1,174,206,082 | -$126,382,516 | $14.61 | 201 |
| 2020 Q4 | 86,846,381 | $1,509,532,138 | +$7,068,870 | $17.38 | 191 |
| 2020 Q3 | 87,967,283 | $1,615,322,964 | -$17,575,985 | $18.34 | 200 |